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Original Article 
Relationship between p53 Expression and Gastric Cancers in Cardia 
and Antrum 
 
Ramin Azarhoush MD*, Abbas Ali Keshtkar MD MPH PhD•**, Taghi Amiriani PhD***,   

Vahideh Kazemi-Nejad MD* 

Background: The mutations in p53 gene and accumulation of p53 protein are the most 
common genetic events in gastric carcinomas. The present study was conducted to compare the 
frequency of p53 gene overexpression in a consecutive series of adenocarcinomas arising from
the cardia and the antrum. This study also evaluates the associations of this gene expression with
demographic and clinicopathologic findings (age, sex, histology, and grade of tumor).  
Methods: Retrospective analysis was performed on 111 patients with gastric cancer who had
undergone upper gastrointestinal endoscopies in 5th Azar Medical Center (northeastern, Iran), 
during 1998-2005. The series comprised of 25 patients with cardia adenocarcinoma and 86 patients 
with antral adenocarcinoma. p53 alteration (nuclear p53 overexpression) was detected by
immunohistochemistry. 
Results: Nuclear p53 overexpression was found in 14 (56%) out of the 25 and 27 (31.3%) out of 
the 86 patients with cardia and antral adenocarcinomas, respectively. p53 gene overexpression
was significantly more frequent in adenocarcinomas of the cardia than the antrum. There were no
differences in the clinicopathologic characteristics of the tumors between p53-positive and p53-
negative cases in both types of the cancer. 
Conclusion: This study shows that p53 alterations correlate well with gastric location, and
they are more frequent in adenocarcinoma of the cardia than the antrum. This result reinforce the 
hypothesis that the cancers of the lower esophagus and upper stomach have distinct
epidemiologic, pathogenesis,  and molecular characteristics from that observed in cancers of the
lower part of the stomach. 
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astric cancer remains the second most 
common cause of cancer-related deaths 
world wide.1–3 However, there are large 
geographic variations in incidence, which may be 
related to environmental and genetic factors.  
In addition to dietary factors such as excessive 
intake of salt and food contaminations with N-
nitrose compounds, cigarette smoking,  and H. 
pylori infection have been regarded as presumed
environmental factors contributing to gastric 
carcinogenesis.4–6 
Mutations in the tumor suppressor gene p53 are
the most frequent genetic alterations in human
cancer. Previous studies of their incidence ranged
from as low as 4% to as high as 57%.7 Recently, 
one study demonstrated that p53 mutations were 
frequently found in H. pylori-associated gastritis, 
suggesting a direct role for H. pylori infection in 
p53 mutagenesis.8 p53 is a tumor suppressor gene.
It is located on the short arm of chromosome 17,
producing a 53 kDa nuclear protein. p53 gene, 
through the production of p53 protein, controls the
cell cycle and prevents genetic mutations for 
carcinogenesis.9 The mutations of the p53 gene are 
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genetic events in the pathogenesis of gastric 
adenocarcinoma.10,11 However, the suggestion 
awaits further investigation for confirmation. 
Rapid increase in p53 levels and activation of
p53 as a transcription factor (shown to have major 
role in carcinogenesis) lead to two major effects: 
cell-cycle arrest and apoptosis. The wild type gene
is capable of arresting growth in transfecting 
experiments.9 In some cases, it sends a cell into a 
programmed spiral of death.10 Mutant forms not 
only deprive beneficial effects of the wild type
cells but also can spur abnormal cell growth.10 p53 
mutation is a common event in gastric carcinoma 
occurring from the early stage of progression with
its specific mutation spectrum.11 With homozygous
loss of p53, DNA damage goes nonrepaired, 
mutations become fixed in dividing cells, and the 
cells turn into malignant transformation.l2,13 
Accumulation of p53 protein in the nuclei of 
carcinomatous cells is known to correlate well with
the presence of mutations in the p53 gene.14,15 
There are several methods for detecting 
molecular alterations in cancer including DNA 
sequencing, polymerase chain reaction (PCR), 
immunoblot, and immunohistochemistry (IHC). 
IHC can be applied to relatively small specimens.
It is simple and fast and is consistent with other 
methodologies.15,16 Therefore, the IHC method has 
been widely used for searching for molecular
markers of cancer, such as p53.
The aim of our study was to document the
frequency and the relationships between 
immunohistochemical expressions of p53 with 
demographic and clinicopathologic findings, and
with the location of stomach cancer.
Materials and Methods 
One hundred and eleven gastric biopsy
specimens taken by fiberoptic endoscopy were 
collected from patients with gastric 
adenocarcinoma. Twenty-five specimens were
gathered from patients with cardia tumor and the
remaining 86 specimens were gathered from antral
tumor. The cases were identified from pathologic 
laboratory files. The patients underwent endoscopy
in 5th Azar Medical Center in Gorgan 
(northeastern Iran) during 1998 – 2005. 
Adenocarcinoma of the cardia was defined as a 
tumor with a center located within 2 cm of the 
esophago-gastric junction.17 No patient had 
received chemotherapy or radiotherapy before 
endoscopic biopsy. Clinicopathologic and 
demographic data (including age, gender, gastric 
location of the tumor, and histologic grade) were 
collected retrospectively in all patients, by 
reviewing the clinical charts and all histologic 
slides. 
The tissue specimens were received in 
formaldehyde (10% solution). The samples 
that were paraffin wax embedded, were sectioned 
and stained serially with hematoxylin and eosin (H
& E) for conventional histopathologic study. For
IHC study, dewaxed 5 µ sections were stained with
the primary antibody p53 (DAKO, Denmark) using 
a three step immunoperoxidase technique
enhanced by microwave heating. Hematoxylin was 
used to counterstain the nuclei lightly. Anti-p53 
antibody is a monoclonal mouse antiserum against 
p53 of human origin, which recognizes both wild 
and mutant type of p53. For negative controls we 
used the omitted primary antibody and for positive 
controls, we used a Barrett's adenocarcinoma with
a positive immunostaining.  
Results were reported positive when at least
20% of cells showed homogeneous and intense 
nuclear staining. All the slides were examined by
two independent observers. 
For statistical analysis we used χ2 test, Fisher’s
exact test, and Kappa test. P<0.05 was considered
significant. 
Results
Eighty-six specimens were collected from 
patients with antral adenocarcinoma and 25 
specimens were collected from patients with cardia 
adenocarcinoma. The patients with cancer of
antrum comprised 67 men and 19 women aged 22
– 89 years (median: 59) and those with cancer of
the cardia comprised 19 men and 6 women aged 24 
– 85 years (median: 65). The tumors of antrum 
comprised 75 cases of intestinal type, and 11 cases
of the diffuse type in Lauren’s classification.17 
The same 86 tumors were examined by IHC.
Twenty-seven (31.3%) of the adenocarcinomas
stained positively with the human p53-specific 
monoclonal antibody (DAKO, Denmark). In these 
cases, the staining was exclusively nuclear and 
stromal cells were unstained. Fifty-nine cases had 
no p53 immunoreactivity. Omission of the primary
antibody resulted in complete abolition of
immunostaining. There was no significant 
difference in the clinicopathologic characteristics
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of the antral tumors between p53-positive and p53­
negative cases (Table 1). 
The tumors of cardia comprised 25 cases, 18 
cases of the intestinal and seven cases of the
diffuse type in Lauren’s classification. The same
25 tumors were examined by IHC. Fourteen (56%) 
of adenocarcinomas stained positively with the 
human p53-specific monoclonal antibody
(DAKO). There was no significant difference in
clinicopathologic characteristics of the cardia
tumors between p53-positive and p53-negative
cases.  
The results did not demonstrate any significant 
association between p53 expression and age, sex,
and histologic type in both locations (cardia and
antrum) (Tables 1 and 2). But there was a
relationship between p53 expression and location. 
The frequency of p53 gene expression (p53 protein 
immunoreactivity) was higher in adenocarcinomas 
of the cardia (14 of the 25) compared with
adenocarcinomas of the antrum (27 of the 86) 
(Chi-square=5.03, P=0.025). 
Discussion
The p53 gene has been indicated to be 
commonly mutated in various human cancers 
(including gastric cancer). Mutant p53 can act as a 
dominant oncogene. The presence of p53 protein 
overexpression is generally thought to indicate the 
presence of p53 gene mutation. The frequency and 
the pattern of p53 mutations might vary with 
geographic origin in gastric cancer, reflecting 
different etiologic agents. A number of studies 
have reported the frequency of p53 alterations in 
gastric cancer, studying either p53 protein 
Relationship between p53 expression and gastric cancers in
cardia and antrum
overexpression or  p53 gene  mutation.18–20  Of 
the gastric adenocarcinomas, 18% to 58% have 
been found to have p53 mutation. P53 protein 
overexpression has been detected in 26 – 65% of 
tumors in the stomach.21–26 
We found p53 expression in 41 cases (36.9%) 
of all gastric cancer tissues. It is compatible with 
the above mentioned research. We found a
relatively high frequency (56%, 14 of 25) of p53
protein overexpression in adenocarcinoma of the
cardia. This frequency was higher than that 
observed in adenocarcinoma of the antrum (31.3%, 
27 of 86). The difference was statistically
significant. 
The frequency of p53 alteration was compared
with the location of the tumors in the stomach, in a 
few studies. Higher frequency of p53 protein
expression in adenocarcinoma of the cardia than in 
the antrum has been reported in various 
studies.19,20,27 Therefore, adenocarcinoma of the 
cardia appears to show a higher frequency of p53
alteration compared with cancer of the lower part
of the stomach. In another study comparing p53
alterations in a consecutive series of esophageal
and cardial adenocarcinoma, a high frequency of
gene mutation (70% vs. 63%) and p53 protein 
production (70% vs. 56%) was observed in both 
groups of tumors.4 
Other site specific differences including DNA
aneuploidy and microsatellite instability have been
reported with respect to the anatomical sites of
tumors.28–30 Molecular similarities between cardia
and esophageal adenocarcinoma are consistent 
with the hypothesis that these cancers share a 
common etiology, distinct from that responsible





















       










     







     
     
Table 1. Status of p53 expression by gender, age groups, histological types, and gastric tumor location
(numbers in the parenthesis are percent).
Factors P53 expression Positive Negative Total χ




34 (82.9) 53 (75.7)





50 – 69 years
≥70 years
14 (34.2) 22 (31.4)
18 (43.8) 33 (47.2)








31 (75.6) 62 (88.6)




Tumor  location 5.03 0.025
Antrum 
Cardia 
27 (65.9) 59 (84.3)
14 (34.1) 11 (15.7)
86 (77.5)
25 (22.5)
Total 41 (100) 70 (100) 111 (100)  














































  Table 2. Location of gastric tumors by gender, age groups, and histological types (numbers in the parenthesis are
percent). 
  Factors	 
 Tumor location
Antrum Cardia Total χ
2  P value
  Gender    0.04 0.84 
 
 
Male  67 (77.9)  19 (76.0)  86 (77.5)
Female  19 (22.1)  6 (24.0)  25 (22.5)   
Age groups     0.70 0.403
<50 years  9 (33.7)  7 (28.0)  36 (32.4)
  50 – 69 years  40 (46.5)  11 (44.0)  51 (46.0)   
 ≥70 years  17 (19.8)  7 (28.0)  24 (21.6)   
Histological types     3.3 0.07
 Intestinal  75 (87.2)  18 (72.0)  93 (83.8)
Diffuse  11 (12.8)  7 (28.0)  18 (16.2)   
Total   86 (100)  25 (100)  111 (100)   
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lower part of the stomach. It has been suggested 
that a comparison of the precise type of p53
mutation might indicate whether similar or distinct
mechanisms of carcinogenesis are involved in
different tumors.3, 31 
We found no association between p53 alteration 
and age, gender, and histological grade. Similar 
results have been reported in most series of
adenocarcinoma of the esophagus and 
stomach,20,27,32 which indicate an early involvement 
of p53 in the development of these cancers.33,34 
Some authors reported a higher incidence of p53
alterations in gastric cancer of the intestinal type in 
comparison with the diffuse type.35,36 We were 
unable to confirm such a feature, maybe because of 
the limited number of cancers of the antrum
showing p53 abnormalities. 
In conclusion, our study revealed higher levels 
of p53 alterations in adenocarcinoma of the cardia 
compared with the antrum. This result reinforce the 
hypothesis that the cancers of the lower esophagus 
and upper stomach have distinct epidemiological, 
pathogenesis, and molecular characteristics from 
that observed in cancers of the lower part of the 
stomach.
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